Clinical Advances in the Treatment of Prostate Cancer:
A Closer Look at the Role of PARP Inhibitors

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of Prostate Cancer

These are archives of live webinars held between February 12, 2021 to February 17, 2021

If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all three or in order.

These activities are valid from March 1, 2021 to March 1, 2023

This series is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Prostate cancer is the most diagnosed non-cutaneous cancer in men in the US and remains the second leading cause of cancer deaths among American men, with an estimated 174,000 new cases diagnosed in 2020. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. Fortunately for these patients, novel therapies have changed the treatment paradigm, as recent data has shown that newer options, including PARP inhibitors, greatly improves outcomes.

Comparative Effectiveness and Payer-Provider Coordination in Prostate Cancer: What Managed Care Needs to Know About Current and Emerging PARP Inhibitors?

1. Identify current unmet economic needs in the management of prostate cancer and evidence-based recommendations for the care of patients with these tumors
2. Review the evolving role of PARP inhibitors in the management of prostate cancer
3. Describe approaches currently utilized by third party payers to manage costs associated with the care of patients with prostate cancer
4. Discuss the managed care considerations of new and emerging PARP inhibitor therapies by exploring where these agents may fit into current prostate cancer management paradigm
5. Assess the role of managed care professionals within the collaborative care team for effective therapy management for patients with prostate cancer

A Closer Look at Emerging PARP Inhibitors in the Treatment of Prostate Cancer: Recent Clinical Trial Data for Improved Clinical and Economic Outcomes

1. Examine current unmet clinical needs in the diagnosis and management of prostate cancer
2. Analyze recent clinical trial data on the efficacy and safety of PARP inhibitor therapies in the management of prostate cancer
3. Assess the role of emerging PARP inhibitors in the evolving prostate cancer treatment paradigm
4. Identify patients who may benefit from emerging PARP inhibitor therapies in the management of prostate cancer, including combination therapy
5. Assess how the potential roles of biomarkers and barriers to adherence play a role in long-term treatment decision making for patients with prostate cancer

Improving Patient Adherence and Quality of Life in Prostate Cancer: Strategies for Managing Treatment Related Adverse Events Associated with PARP Inhibitor Regimens

1. Examine challenges to patient adherence, administration and quality of life in the management of prostate cancer
2. Discuss strategies to implement PARP inhibitors into the treatment paradigm, especially as it relates to patient adherence and quality of life
3. Define strategies for anticipating, recognizing, and managing adverse events of PARP inhibitor therapy in patients with prostate cancer
4. Explore the role of PARP inhibitors in the management of prostate cancer